Enveda, a clinical-stage biotechnology company based in Boulder, Colorado, has closed a $311 million Series E financing round led by Catalio Capital Management. The investment brings the company's total capital raised since inception to more than $845 million and adds new healthcare and technology investors to its syndicate. The funding follows two positive early clinical readouts in 2026 for medicines discovered through Enveda's artificial intelligence platform PRISM.
Investor Syndicate and Board Appointment
The round unites investors with experience across technology and healthcare. In addition to Catalio Capital Management, new investors include Durable Capital Partners, ICONIQ, Lightspeed, Surveyor Capital, accounts advised by T. Rowe Price Investment Management, Digitalis Ventures, a sovereign wealth fund, and Alderline Group. Existing investors including Baillie Gifford, Premji Invest, FPV Ventures, True Ventures, Kinnevik, Dimension, Lifeforce Capital, and Lux Capital also participated, and Catalio's George Petrocheilos joined Enveda's board.
Investor Perspectives
Viswa Colluru, Founder and CEO of Enveda, said the financing validates the company's view that natural chemistry refined over billions of years is a reliable source of new medicines. Catalio Capital Management Co-Founder George Petrocheilos described Enveda as a full-stack, AI-enabled platform with a repeatable pipeline. Alex Gorsky, General Partner at ICONIQ and former Johnson & Johnson chief executive, noted that early clinical data suggest the approach could represent an important healthcare milestone.
Use of Proceeds
Enveda plans to use the proceeds to advance its clinical-stage medicines into later-phase development and additional indications. The company expects to start new trials in the coming months and to move ENV-6946 through mid-phase trials. Capital will also support further scaling of the PRISM platform and the automated laboratory that feeds it, along with new programs for inflammatory and metabolic conditions.
Clinical Validation Across Multiple Programs
ENV-294, a once-daily treatment for eczema and asthma, showed an average 85 percent improvement in eczema severity after 42 days in a Phase 1b study with no serious side effects. Phase 2 trials are underway, and additional data will be presented at the European Academy of Dermatology and Venereology Congress on October 1, 2026. ENV-308 was well tolerated in 88 healthy volunteers and lowered circulating leptin, while ENV-6946 is now in Phase 1 for inflammatory bowel disease.
Platform and Discovery Strategy
Enveda's PRISM foundation model is trained on the chemistry of living organisms and identifies molecules that already exist in plants, microbes, and the human body. The company estimates that nearly half of oral medicines originate from natural molecules, yet 99 percent of nature's chemical diversity remains unexamined. Since 2019, the platform has produced 17 development candidates, three of which have entered human trials with first-in-class mechanisms.
Leadership and Operational Scale
Enveda has strengthened its clinical development leadership with hires from companies that have taken first-in-class medicines through late-stage trials and to market. Nadeem Sarwar joined from Novo Nordisk, Michael Charlton from Madrigal Pharmaceuticals, and Doug Maslin from LEO Pharma. The company is also applying its artificial intelligence capabilities to manufacturing, quality, and clinical trial operations to support the next stage of growth.
The Series E financing positions Enveda to move multiple clinical programs forward while continuing to expand the PRISM platform. The participation of both healthcare and technology investors highlights confidence in the company's AI-native approach to drug discovery. Enveda's progress with ENV-294 and ENV-308 suggests that its method of learning from natural chemistry could yield new treatment options for inflammatory and metabolic diseases.